Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
Table 2
Periprocedural characteristics.
Parameter
BiOSS group
DES group
No ISR
ISR
No ISR
ISR
(%)
(%)
(%)
(%)
MV predilatation
117 (59.1)
20 (83.3)
145 (70.4)
14 (82.4)
SB predilatation
67 (33.8)
7 (29.2)
57 (27.7)
8 (47.1)
Nominal stent diameter [mm]
–
–
3.34 ± 0.45
3.22 ± 0.51
Nominal stent diameter in MV [mm]
3.70 ± 0.33
3.72 ± 0.41
–
–
Nominal stent diameter in MB [mm]
3.01 ± 0.34
3.00 ± 0.38
–
–
Nominal stent length [mm]
17.44 ± 1.54
18.21 ± 2.50
20.28 ± 4.32
20.53 ± 5.62
Sirolimus eluting
88 (44.4)
14 (58.3)
148 (71.8)
7 (41.2)
Paclitaxel eluting
110 (55.6)
10 (41.7)
58 (28.2)
10 (58.8)
POT
81 (40.9)
2 (8.3)
152 (73.8)
1 (5.9)
FKB
65 (32.8)
6 (25)
101 (49)
9 (52.9)
stent in SB
17 (8.6)
5 (20.8)
7 (3.4)
8 (47.1)
No ISR vs. ISR in BiOSS or rDES groups. ISR between BiOSS and rDES groups. FKB: final kissing balloon; ISR: in-stent restenosis; MB: main branch; MV: main vessel; POT: proximal optimization technique; SB: side branch.
